Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Dapagliflozin on Body Weight in Japanese Patients with Type 2 Diabetes Mellitus (SUMS-ADDIT-2)
jRCTs051180018Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of dapagliflozin in type 2 diabetes mellitus (T2DM), obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by AstraZeneca. Primary endpoint: Change in body weight at 24 weeks. Started Mar 2016; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)obesitymetabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on jRCTs051180018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180018.